Biology Strategy Meeting

B2B BIOLOGY
STRATEGY MEETING USA EAST COAST 2018

Sheraton Boston Hotel
Wednesday 14TH November, 2018
OUR UNIQUE MEETING FORMAT

BIOLOGY Roundtable Discussions CONTRIBUTORS TO THE AGENDA
These interactive and informal discussion groups are the hallmark of the meeting.
Small exclusive groups of Leaders who face shared challenges and strategic priorities
COVER are brought together in 60-minute sessions that enable participants to share ideas Vikram Kansra
and lessons learned. Facilitated by experienced professionals, these sessions provide Vice President and Head Clinical Pharmacology &
a valuable dialogue with peers on current challenges and topical issues. Each
Drug Disposition
AGENDA-AT-A-GLANCE discussion group has limited numbers which ensures each delegate is given ample
opportunity to raise questions and contribute to the discussion. TESARO
DMPK & ADME Personalised Agenda Jennifer Michaelson
Each delegate receives a personalised agenda combining industry-leading keynote
In Vivo & In Vitro Vice President, Preclinical Research and Early
presentations, topical roundtable discussions, networking and business meetings.
Pharmacology You only attend sessions and meetings that fit your challenges and interests, Development
ensuring your time out of the office is focused and well-utilised. Cullinan Oncology
Structural Biology &
Biophysics One-to-one Meetings
The most effective and time efficient way to assess potential partners at a strategic Clark Pan
Toxicology level. Compare and update your knowledge of the industry in 25-minutes informative
Vice President, Head of Discovery Therapeutics
and relaxed business meetings with solution providers of your choice.
Strategic Partnership & Shire
Outsourcing
Networking
Strategic networking opportunities form a key benefit of participating in the meeting. Girish Aakalu
Our proven format for building and strengthening alliances is underscored by a host
of networking programmes, from casual networking activities such as lunches as Vice President and Head of Global Scientific
PARTICIPANTS Affairs & Scientific Intelligence
well as formal networking opportunities that are built into your personalised agenda.
Panel Discussion Ipsen

SPONSORS
Industry-leading professionals share their experiences in high-level
strategic case study-based presentation. Laszlo Urban
HOTEL & TRAVEL Global Head, Preclinical Secondary Pharmacology
Novartis Institutes for BioMedical Research
“The format is quite good, I think the best part of the format is you get informal opinions about
HEAR ABOUT current status of research from the folks of medicinal chemistry industry.” Anthony Bahinski
OUR FORMAT - Executive Director, Chemistry, ARMGO Pharma Global Head, Safety Pharmacology
GlaxoSmithKline
“The roundtable discussion is an excellent meeting, the size of the people on the table is
appropriate, not too large and not too small so all the people in the audience will have a Byron DeLaBarre
chance to participate.” Director of Structural Biology
- Executive Vice President Chemistry, Evotec
Nimbus Therapeutics
John Soglia
Head of Drug Disposition and Quantitative ADME Sciences
Proventa International, Unit 51
Skylines Business Village
Decibel Therapeutics
+44 20 7096 1222
Limeharbour, London E14 9TS
United Kingdom www.proventainternational.com
B2B BIOLOGY
BIOLOGY
IN VIVO & IN VITRO STRUCTURAL BIOLOGY & STRATEGIC PARTNERSHIP
TRACKS DMPK & ADME TOXICOLOGY
PHARMACOLOGY BIOPHYSICS & OUTSOURCING
COVER
08:00-08:30 REGISTRATION & BREAKFAST NETWORKING
AGENDA-AT-A-GLANCE 08:30-09:00 WELCOME SPEECH & KEYNOTE PRESENTATION

DMPK & ADME 09:00-10:00 How application of PBPK Biologics drug development Combining X-ray and cryo-EM Integrating lead optimization Improving alliances with more
modelling can influence in oncology/immuno- to study large and dynamic and risk assessment strategies effective collaborations
In Vivo & In Vitro decision-making throughout oncology: in vitro and in vivo macromolecular complexes Title TBC
Pharmacology drug development pharmacology studies Laszlo Urban,
Byron DeLaBarre, Novartis Institutes for Clark Pan,
Structural Biology & John Soglia, Jennifer Michaelson, Nimbus Therapeutics BioMedical Research Shire
Biophysics Decibel Therapeutics Cullinan Oncology
Toxicology 10:00-10:05 MORNING BREAK

Strategic Partnership & 10:05-10:30 1-1 MEETINGS / NETWORKING
Outsourcing
10:30-10:35 BREAK
PARTICIPANTS
10:35-11:00 1-1 MEETINGS / NETWORKING
SPONSORS 11:00-12:00 Early ADME and DMPK Target validation using in-vitro Monitoring protein structural Using of pharmacogenomic Developing robust metrics
predictions for better lead and in-vivo pharmacology changes on a proteome-wide and pharmacoepigenomic for improving relationship
optimization Title TBC tools (First-in-class targets): scale Title TBC biomarkers for drug efficacy management Title TBC
HOTEL & TRAVEL challenges and perspectives and toxicity Title TBC
DiscoverX WuXi Apptec WuXi Apptec
Saravanakumar DiscoverX
Dhakshinamoorthy (SK),
Jubilant Biosys
HEAR ABOUT
OUR FORMAT 12:00-12:05 BREAK
12:30-12:35 BREAK
13:00-14:00 LUNCH

Skylines Business Village +44 20 7096 1222
B2B BIOLOGY
BIOLOGY
IN VIVO & IN VITRO STRUCTURAL BIOLOGY & STRATEGIC PARTNERSHIP
TRACKS DMPK & ADME TOXICOLOGY
PHARMACOLOGY BIOPHYSICS & OUTSOURCING
COVER
KEYNOTE PRESENTATION
14:00-14:30
AGENDA-AT-A-GLANCE Gregg Siegel, Chief Executive Officer, ZoBio B.V.
DMPK & ADME 14:30-15:30 Predicting human ADME Novel in vitro and in vivo Analysing solutions to Assessing the abuse potential Establishing a new CRO
Parameters models for the study of drug monitor and optimise of CNS active drugs: regulatory partnership model in support
In Vivo & In Vitro transporters in discovery and protein complexes in and methodological of improved cycle times
Pharmacology Confirmed for Sponsor development Title TBC structural biology and drug considerations
development Confirmed for Sponsor
Structural Biology & WuXi Apptec Confirmed for Sponsor
Biophysics Confirmed for Sponsor
Toxicology
15:30-15:35 AFTERNOON BREAK
Strategic Partnership &
Outsourcing 15:35-16:00 1-1 MEETINGS / NETWORKING
16:00-17:00 Adoption of ADME models in Designing and Engineering Identifying new tools for Bridging the translational
PARTICIPANTS drug discovery The role of clinical Antibody Therapeutics for safety screening: organs-on- medicine gap between in
pharmacology and modeling difficult-to-target proteins chips-, iPSC and 3D cell-based vitro assays and in vivo drug
Facilitator to be Announced and simulation in drug assays, humanized animal response assessment
SPONSORS development Facilitator to be Announced models
Girish Aakalu,
Vikram Kansra, Anthony Bahinski, Ipsen
HOTEL & TRAVEL TESARO GlaxoSmithKline
HEAR ABOUT
17:00-17:30 CLOSING SPEECH & PANEL DISCUSSION
OUR FORMAT
17:30-18:30 DRINKS & CONVERSATION

B2B BIOLOGY
D MPK & ADME

BIOLOGY
COVER John Soglia

Head of Drug Disposition and Quantitative ADME sciences
Decibel Therapeutics
AGENDA-AT-A-GLANCE
How application of PBPK modelling can influence Early ADME and DMPK predictions for better lead
DMPK & ADME 09:00-10:00 decision-making throughout drug development 11:00-12:00 optimization Title TBC
In Vivo & In Vitro

Pharmacology

Biophysics
Toxicology

Outsourcing
PARTICIPANTS
SPONSORS Confirmed for Sponsor Facilitator to be Announced
HOTEL & TRAVEL

14:30-15:30 Predicting human ADME Parameters 16:00-17:00 Adoption of ADME models in drug discovery
HEAR ABOUT
OUR FORMAT

B2B BIOLOGY
IN VIVO & IN VITRO

PHARMACOLOGY
BIOLOGY
COVER Jennifer Michaelson Saravanakumar Dhakshinamoorthy (SK)

Vice President, Preclinical Research and Early Development Vice President
Cullinan Oncology Jubilant Biosys
AGENDA-AT-A-GLANCE
Biologics drug development in oncology/immuno- Target validation using in-vitro and in-vivo pharmacology
DMPK & ADME 09:00-10:00 oncology: in vitro and in vivo pharmacology studies 11:00-12:00 tools (First-in-class targets): challenges and perspectives
In Vivo & In Vitro

Pharmacology Selecting a development candidate Development and validation of robust in-vitro and in-vivo pharmacology tools/
models for target validation
Preclinical studies to support IND submission
Structural Biology & Accelerated timelines – opportunities and challenges Impact of the quality of biological and Pharmacological reagents in the outcome
of target validation exercise
Biophysics
Challenges with the correlation & interpretation of the validation data from in-
vitro/ in-vivo pharmacology studies
Toxicology

Outsourcing
PARTICIPANTS
Vikram Kansra
SPONSORS Vice President and Head Clinical Pharmacology &
Drug Disposition, TESARO
HOTEL & TRAVEL Novel in vitro and in vivo models for the study of drug The role of clinical pharmacology and modeling and
14:30-15:30 transporters in discovery and development Title TBC 16:00-17:00 simulation in drug development
HEAR ABOUT
OUR FORMAT

B2B BIOLOGY
STRUCTURAL
BIOLOGY & BIOPHYSICS
BIOLOGY
COVER Byron DeLaBarre

Director of Structural Biology
Nimbus Therapeutics
AGENDA-AT-A-GLANCE
Combining X-ray and cryo-EM to study large and dynamic Monitoring protein structural changes on a proteome-
DMPK & ADME 09:00-10:00 macromolecular complexes 11:00-12:00 wide scale Title TBC
In Vivo & In Vitro

Pharmacology

Biophysics
Toxicology

Outsourcing
PARTICIPANTS
HOTEL & TRAVEL Analysing solutions to monitor and optimise protein Designing and Engineering Antibody Therapeutics for
14:30-15:30 complexes in structural biology and drug development 16:00-17:00 difficult-to-target proteins
HEAR ABOUT
OUR FORMAT

B2B BIOLOGY
TOXICOLOGY
BIOLOGY
COVER Laszlo Urban

Global Head, Preclinical Secondary Pharmacology
Novartis Institutes for BioMedical Research
AGENDA-AT-A-GLANCE
Integrating lead optimization and risk assessment Using of pharmacogenomic and pharmacoepigenomic
DMPK & ADME 09:00-10:00 strategies 11:00-12:00 biomarkers for drug efficacy and toxicity Title TBC
In Vivo & In Vitro

Pharmacology

Biophysics
Toxicology

Outsourcing
PARTICIPANTS
Anthony Bahinski
SPONSORS Confirmed for Sponsor Global Head, Safety Pharmacology
GlaxoSmithKline
HOTEL & TRAVEL Identifying new tools for safety screening:

Assessing the abuse potential of CNS active drugs:
14:30-15:30 16:00-17:00 organs-on-chips-, iPSC and 3D cell-based assays,
regulatory and methodological considerations
humanized animal models
HEAR ABOUT
OUR FORMAT

B2B BIOLOGY
STRATEGIC
PARTNERSHIP & OUTSOURCING
BIOLOGY
COVER Clark Pan

Vice President, Head of Discovery Therapeutics
Shire
AGENDA-AT-A-GLANCE
Improving alliances with more effective collaborations Developing robust metrics for improving relationship
DMPK & ADME 09:00-10:00 Title TBC 11:00-12:00 management Title TBC
In Vivo & In Vitro

Pharmacology

Biophysics
Toxicology

Outsourcing
PARTICIPANTS
HOTEL & TRAVEL Establishing a new CRO partnership model in support of Bridging the translational medicine gap between in vitro
14:30-15:30 improved cycle times 16:00-17:00 assays and in vivo drug response assessment
HEAR ABOUT
OUR FORMAT

B2B BIOLOGY
WHO SHOULD ATTEND?

BIOLOGY
Thought leaders who will benefit from attending include:
COVER Chief Executive Officers
AGENDA-AT-A-GLANCE
Senior Vice Presidents
Executive Vice Presidents
DMPK & ADME
Vice Presidents
In Vivo & In Vitro
Pharmacology Executive Directors
Structural Biology & Directors
Biophysics Global Heads
Toxicology
Strategic Partnership & Responsible for:

Outsourcing
DMPK
PARTICIPANTS Computational
Drug metabolism
SPONSORS
ADME Toxicologist
HOTEL & TRAVEL PK/PD modeling
Toxicologist
Anatomy
HEAR ABOUT
OUR FORMAT
Stem cell
Structural Biology and Biophysics
Indication Expansion
Strategic Partnerships and Alliances
Global Commercialization/Strategy
Program and Portfolio Development
Strategy and Portfolio Solutions
B2B BIOLOGY
2018 SPONSORS
BIOLOGY
COVER
ASSOCIATE SPONSOR
WuXi AppTec is a leading pharmaceutical, biopharmaceutical, and medical device open-access platform global company. As an innovation-
driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services that enables drug and medical
AGENDA-AT-A-GLANCE device R&D through cost-effective and efficient solutions. WuXi’s Oncology Unit possesses world leading oncology and immuno-oncology
platforms providing a comprehensive panel of tumor model systems, including human cancer cell line-derived xenograft models, murine
DMPK & ADME syngeneic tumor models, humanized animal models and patient-derived xenograft (PDX) models with in-depth genomic characterization.
Our proprietary database – OncoWuXi – has 1200+ tumor models with full annotation. WuXi Oncology also has strong expertise in CRISPR
In Vivo & In Vitro and specialized tumor cell biology assays.
Pharmacology

Biophysics THOUGHT LEADER
Toxicology
Eurofins DiscoverX develops, manufactures, and commercializes reagents, cell-based assay, profiling and screening services as well as other
turnkey solutions for the drug discovery, screening, and life science markets. Our biochemical and cell-based assays enable customers to
Strategic Partnership & improve research productivity and effectiveness of their screening, lead optimization, and SAR campaigns, thus accelerating the discovery
Outsourcing and development of new drugs. Along with BioMAP platform of human primary cell systems for phenotypic profiling, and the combined
capabilities of Eurofins Pharma Discovery Services, DiscoverX offers powerful platforms to deliver physiologically relevant insights and
integrated solutions for all stages of drug discovery.
PARTICIPANTS
SPONSORS
CO-HOST SPONSORS
HOTEL & TRAVEL
Dotmatics delivers a ready-to-use platform to capture, register, share, collaborate, query, visualise and analyse all the information and
knowledge generated in the modern, highly collaborative scientific industries. Dotmatics has significant expertise in scientific informatics,
including database management for chemistry and biologics, electronic laboratory notebooks, chemical and biological registration,
screening data management, SAR analysis, reporting, and visualisation.
HEAR ABOUT
OUR FORMAT
Pelago Bioscience AB provides and develops the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and
quantification of drug–target interactions. The company delivers in situ target engagement studies to accelerate drug discovery and
diagnostics development. CETSA® provides a quantitative measure of Target Engagement and biophysical readout of affinity, adding
real value to existing efficacy assays. We deliver complete target engagement data sets, develop and validate assays, and profile candidate
drugs based on the CETSA® method applications tailored to the project need. For larger volumes and portfolios we offer tech transfer and
sublicensing of the CETSA® method.

B2B BIOLOGY
2018 SPONSORS
BIOLOGY
COVER
CO-HOST SPONSORS
Jubilant Drug Discovery Solutions (JDDS) comprises Jubilant Biosys and Jubilant Chemsys and has a presence in Bangalore and
Noida, India. The company has over 625 employees and has demonstrated expertise in multiple therapeutic areas including Oncology,
AGENDA-AT-A-GLANCE Metabolic Disorders, Pain & Inflammation, and CNS. Our business model includes proprietary in-house innovation, and drug discovery
services which are available for collaborative research, partnership and out-licensing. Our capabilities: medicinal chemistry, in vitro and
DMPK & ADME in vivo pharmacology, DMPK, structural biology, GLP and non-GLP toxicology, as well as GMP and non-GMP scale-up services.
For more info: www.jubilantbiosys.com, www.jubilantchemsys.com
In Vivo & In Vitro
Pharmacology
PerkinElmer Informatics delivers software and services globally for research, discovery, analysis and collaboration across multiple industries
Structural Biology & including biopharmaceutical, food and chemical industries, academia and government. PerkinElmer’s Ensemble platform, now with
Biophysics TIBCO Spotfire®, supports crucial informatics research and development activities as well as clinical & manufacturing. Products include
ChemDraw®, E-Notebook and LES systems for knowledge management and integrated laboratory systems.
Toxicology

ZoBio is the leading biophysics CRO providing a complete range of services from gene to structure based drug discovery. To begin we
Outsourcing
enable structural biology (using both NMR and X-ray crystallography) on targets where others have failed. We continue with proprietary
NMR and Biacore methods for fragment library screening, hit validation, HTS hit triage and hit-to-lead support in conjunction with our
structural biology capabilities. In its more than 10 years of existence, ZoBio has supported some 70 programs with a rich diversity of targets
PARTICIPANTS
including PPIs, an array of epigenetic targets and even GPCRs, some of which are now in the clinic.
SPONSORS
Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise. Founded in 2004,
Sygnature operates a fully-enabled research facility in Nottingham, housing >230 experienced research scientists (80% with PhDs) with
HOTEL & TRAVEL the professional skills required to take on board the most demanding of drug discovery programs and drive them towards a successful
outcome. The company undertakes target validation, hit identification, hit-to-lead and lead optimization. Sygnature’s capabilities include
medicinal and computational chemistry, in vitro biology/screening, DMPK, Discovery Toxicology and protein crystallography (with affiliate,
Peak Proteins). Since 2011, 12 of the 24 drug candidates invented at Sygnature have already entered the clinic (Phases I and II).
HEAR ABOUT
OUR FORMAT

B2B BIOLOGY
2018 SPONSORS
BIOLOGY
COVER
AGENDA-AT-A-GLANCE
DMPK & ADME
In Vivo & In Vitro

Pharmacology
2018 MEDIA & SUPPORTING PARTNERS

Biophysics
Toxicology

Outsourcing
CrowdReviews
Buyers Guide Based On Client Reviews
PUBLICATIONS
PARTICIPANTS The Pharma Review®
SPONSORS
HOTEL & TRAVEL
HEAR ABOUT
OUR FORMAT

B2B BIOLOGY
HOTEL & TRAVEL

BIOLOGY
VENUE
COVER
39 Dalton Street, Boston,MA, 02199,
AGENDA-AT-A-GLANCE
United States
DMPK & ADME
Tel: +1 617 236 2000
In Vivo & In Vitro
Pharmacology DISCOUNT GROUP RATE:
Structural Biology & USD 289 plus charges & Taxes
Biophysics
DISCOUNT ROOM RATE CUT OFF:
Toxicology
13TH October 2018
Outsourcing
GROUP CODE:
PARTICIPANTS PK13AC
SPONSORS
BOOK ONLINE NOW!
HOTEL & TRAVEL
HEAR ABOUT
OUR FORMAT
CLICK
HERE
for more details

Skylines Business Village
MAP & DIRECTIONS

+44 20 7096 1222

Biology Strategy Meeting

Enviado por

Dados do documento

Direitos autorais

Formatos disponíveis

Compartilhar este documento

Compartilhar ou incorporar documento

Opções de compartilhamento

Você considera este documento útil?

Este conteúdo é inapropriado?

Direitos autorais:

Formatos disponíveis

Biology Strategy Meeting

Enviado por

Direitos autorais:

Formatos disponíveis

B2B BIOLOGY

STRATEGY MEETING USA EAST COAST 2018

OUR UNIQUE MEETING FORMAT

Panel Discussion Ipsen

AGENDA-AT-A-GLANCE 08:30-09:00 WELCOME SPEECH & KEYNOTE PRESENTATION

Toxicology 10:00-10:05 MORNING BREAK

12:05-12:30 1-1 MEETINGS / NETWORKING

12:35-13:00 1-1 MEETINGS / NETWORKING

Proventa International, Unit 51

17:30-18:30 DRINKS & CONVERSATION

Proventa International, Unit 51

D MPK & ADME

COVER John Soglia

In Vivo & In Vitro

Structural Biology &

Strategic Partnership &

SPONSORS Confirmed for Sponsor Facilitator to be Announced

HOTEL & TRAVEL

Proventa International, Unit 51

IN VIVO & IN VITRO

COVER Jennifer Michaelson Saravanakumar Dhakshinamoorthy (SK)

In Vivo & In Vitro

Strategic Partnership &

Proventa International, Unit 51

COVER Byron DeLaBarre

In Vivo & In Vitro

Structural Biology &

Strategic Partnership &

SPONSORS Confirmed for Sponsor Facilitator to be Announced

Proventa International, Unit 51

COVER Laszlo Urban

In Vivo & In Vitro

Structural Biology &

Strategic Partnership &

HOTEL & TRAVEL Identifying new tools for safety screening:

Proventa International, Unit 51

COVER Clark Pan

In Vivo & In Vitro

Structural Biology &

Strategic Partnership &

SPONSORS Confirmed for Sponsor Facilitator to be Announced

Proventa International, Unit 51

WHO SHOULD ATTEND?

Strategic Partnership & Responsible for:

Structural Biology &

Proventa International, Unit 51

Strategic Partnership &

Proventa International, Unit 51

DMPK & ADME

In Vivo & In Vitro

2018 MEDIA & SUPPORTING PARTNERS

Strategic Partnership &

HOTEL & TRAVEL

Proventa International, Unit 51

HOTEL & TRAVEL

Proventa International, Unit 51

MAP & DIRECTIONS

Você também pode gostar